LumiraDx Limited (NASDAQ:LMDX) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET

Company Participants

Colleen McMillen - Vice President, Communications

Ron Zwanziger - Chairman and CEO

Dorian LeBlanc - Chief Financial Officer

Conference Call Participants

Jeffrey Cohen - Ladenburg Tallman

Andrew Cooper - Raymond James

Operator

Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the call over to Colleen McMillen. Please go ahead.

Colleen McMillen

Hello, everyone. We'd like to welcome you to today's call to discuss LumiraDx third quarter 2022 financial results issued earlier today. With us are Lunar Dax's Chairman and CEO, Ron Zwanziger' and Chief Financial Officer, Dorian LeBlanc, the press release announcing our financial results is posted on the Investor Relations section of the Company's website at lumiradx.com.

Before we begin, I would like to caution listeners that any statements we make today other than historical facts, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The -- please be aware that all such forward-looking statements involve risks and uncertainties such as those detailed in our annual report on Form 20-F for the year ended December 31, 2021, which is filed with the SEC on April 13, 2022, and our reports on Form 6-K that was filed with the SEC on August 16, 2022, and in other filings that we make with the SEC. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially.

Also, during the course of today's call, we may refer to certain non-IFRS financial measures. Non-IFRS financial measures should not be considered in isolation from or as a substitute for financial information presented in compliance with IFRS -- there is a reconciliation schedule showing that IFRS versus non-IFRS results currently available in our press release issued earlier today, which can be found on our website at lumeradx.com. I will now turn the call over to Ron Zwanziger for opening remarks. We will then provide financial and business updates before answering questions. Ron?

Ron Zwanziger

Thanks, Colleen. Good morning, everyone, and thank you for joining our third quarter '22 results call. As announced this morning, we continue to make progress commercializing new products to rise. At the same time, we've achieved substantial cost savings from restructuring with further scope to exceed our original target. These efforts advance our strategy to transform point of care diagnostics while strengthening our financial position.